Ann: Mesoblast Type A Meeting with FDA, page-93

I think the devil is in the details here as usual. And we do not know the details. What exact elements of the potency assays are being requested as missing from the information already provided? And how will these be addressed and provided by Mesoblast? knowing this would be very helpful in assessing the situation from an investment perspective. All we have here to rely on is the fact that Mesoblast has told us this announcement is NOT impacting MSB price. We can read into that statement in many ways. The announcement also includes various positive elements, all contingent however on the successful presentation by Mesoblast of the additional data to the satisfaction of FDA. I'm invested here since about 2017 and certainly have seen a lot of ups and downs. at this point we are close to finality and I am positive on the potential for a successful outcome in the short term.